With over 70 years of experience, Charles River has a unique and comprehensive portfolio to support the development and execution of cellular therapy programs from animal model selection to discovery and safety evaluations through to clinical and CMC testing support. Our facilities in the United States, Canada, Britain, Finland, Netherlands, and Germany form a global scientific network, allowing us to provide our clients with flexible, comprehensive solutions to maximize resources and optimize results.
- Animal Models
- Efficacy & Safety Assessment
- Regulatory & Clinical Translation
- Biologics Testing Solutions
- Microbial ID
- Endotoxin Testing
Careful choice of a species is a must for cellular therapy programs, one that is both appropriate for proof of concept studies and pharmacologically sensitive that will serve as a progressive host for the specific therapeutic in development in consideration of the intended clinical route of administration. Multiple Charles River locations offer immunodeficient rodent models, large animal models, neonates, surgically altered models, and tumor/syngeneic models for both pilot and safety assessment studies for a range of therapeutic areas including but not limited to inflammation, bone disease, neuroscience research, and metabolic disease. Our surgeons have vast experience in surgical cell implantation methods which mimic clinical routes of administration (e.g., injection into the brain or spinal cord using stereotaxic devices or intraocular instillations).
Case Study: Evaluating Multiple Vectors in a Single Eye
A custom surgical technique to create four independent subretinal injection sites within a single eye for a gene vector.
Related Products & Services
- Genetically Engineered Animal Models & Services
- Immunodeficient Mice & Rats
- Surgical Models
- Syngeneic Mouse Models
In vivo stem cell engraftment: Learn how engrafting various types of stem cells into animal models can predict translation to human patients.
In vivo imaging: Translational preclinical imaging methods that bridge preclinical studies in small animals and clinical endpoints.
Engineered antibody libraries: To develop immune cell therapies.
Stem cell platforms: Improve translation and reduce risk of clinical failure with disease-relevant human induced pluripotent stem cells (iPSCs) derived cells.
Cell Microarray Technology: To uncover exploitable drug targets and screen for potential off-targets.
Critical elements of a preclinical program strategy for a cellular therapy product include a well-characterized product, clinically relevant and robust animal models that allow for characterization of exposure and effects expected in humans, and reliable and sensitive methods of cell detection. These tools are used in characterization, proof of concept, pilot and definitive biodistribution studies, as well as toxicity evaluations. While using available guidance and objectives from traditional toxicology programs in planning safety studies, we advise taking a multidisciplinary approach and partnering with us to build a team of our toxicology experts, immunologists, discovery scientists, and regulatory advisors who will work closely with regulatory reviewers at the Center for Biologics Evaluation (CBER) and other regulatory authorities to ensure program success.
Related Products & Services
- In Vivo Pharmacology Studies
- Molecular Imaging
- Molecular Biology
- Molecular Pathology
- Immunohistochemistry & In Situ Hybridization
- Toxicology Services
- Immunogenicity Assays
- How to Design & Execute Successful CAR T Cell Therapy Programs (Available in The Source℠)
- A Pathologist’s Perspective on Developing and Evaluating Stem Cell Therapeutic Products (Available in The Source℠)
- Use of pluripotent stem cells and stem cells derived neurons in support of drug discovery and target validation (Available in The Source℠)
- Graft versus host disease in CD34+ human hematopoietic stem cell treated NSG mice
- In Vitro Cytotoxicity Testing of CAR T Cells
Our scientific experts, including a former FDA reviewing pharmacologist at the Centers for Drug Evaluation and Biologics Evaluation (CDER & CBER), have a deep understanding of regulatory expectations to help design the best strategy to advance a cellular therapy program. Having this scientific support is particularly crucial for cellular therapy, as reviewers at CBER/FDA highly encourage pre-IND meetings from the Office of Cell, Gene, and Tissue Therapy at the start of each program to discuss current standards of practice in relation to the specific cellular therapy being developed. Not only can they assist with IND filing, but they can also help to identify clinical trial risk mitigation steps, establish clinical biomarkers to address translation gaps, and prepare for BLA filing.
In order to develop a cellular therapy program that meets regulatory expectations, the cell source, type, and degree of manipulation must be considered to establish well characterized cell product manufacturing practices and controls that assure product quality and consistency, essential to safety studies. Charles River’s characterization capabilities include identity and composition, viability and stability as well as purity and sterility. To properly identify the cells, a series of translation biomarkers must be developed, including morphology, surface, and genetic markers–qualified and optimized for the cell target that reveal pharmacologic actions that are then used for lot release and serve as tools for evaluating in vivo safety study results.
In addition, all manufacturers of cellular therapy products are required to assess the ability of the manufacturing process to generate a product safe for human use. Therefore, a viral clearance study is performed to evaluate key steps of the manufacturing process to ensure that it is effective at removing or inactivating viruses. Our scientists have extensive experience in the design and performance of viral clearance studies and we take a customized approach in the selection of process steps and model viruses, scaling-down of purification processes, and subsequent design of study protocols to ensure a successful program is established and reported to meet timelines.
Inaccurate identification of microorganisms, within your facility, can halt product production during parametric release. AccuGENX-ID® utilizes Sanger sequencing technology, our BacSeq bacterial identification of the 16S rRNA gene and FunITS fungal identification of the ITS2 region. These services offer reliable and accurate results in as little as six hours.
Similar to our AccuGENX-ID® methods for bacterial and fungal identification, our AccuGENX-ST® sequence typing uses standard molecular biological methods to characterize your isolates to the strain level. The resulting DNA sequences, or sequence types, are compared to others in a database and the relationships, similarities and/or differences, are displayed in a phylogenetic tree. Providing accurate strain level characteristics allows you to definitively track the source of contamination and/or verify and track known production strains within your facility.
- Fungal Identification with AccuGENX-ID® FunITS
- Bacterial Identification with AccuGENX-ID® BacSeq
- Protein-Coding Gene Sequencing with AccuGENX-ID® ProSeq
- AccuBLAST® Sequencing Data Analysis
Endosafe® cartridge technology offers features that will particularly benefit Cell and Gene Therapy labs due to the nature and volume of samples produced by cell and gene therapies. Endosafe cartridge technology can be used with our handheld, portable rapid endotoxin testing Endosafe® nexgen-PTS™ or our multi-cartridge system, Endosafe® nexgen-MCS™, for results in 15 minutes. Because the archived standard curve is included in the LAL endotoxin testing cartridge, the nexgen-PTS or nexgen-MCS is easy to use and technician variability is reduced meaning lower retest rates saving you time and resources. The Endosafe cartridge technology offers swift results, which allows cell and gene therapy firms to release life-saving product quickly.